Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum β-lactamase

C. E. Smith, B. S. Tillman, A. W. Howell, R. N. Longfield, J. H. Jorgensen

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

A multiple trauma patient failed treatment with ceftazidime and amikacin for bacteremia and meningitis due to a Klebsiella pneumoniae strain that produced a novel, plasmid-mediated β-lactamase. Both pre- and posttreatment isolates were resistant to ceftazidime (MIC, ≥ 64 μg/ml) and various penicillins but not to other expanded-spectrum cephalosporins. The β-lactamase had a pI of 5.25 and was encoded on the conjugal plasmid of approximately 150 kilobases. DNA hybridization studies indicated that the enzyme was a TEM derivative.

Original languageEnglish (US)
Pages (from-to)1290-1293
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume34
Issue number6
DOIs
StatePublished - 1990

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology

Fingerprint

Dive into the research topics of 'Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum β-lactamase'. Together they form a unique fingerprint.

Cite this